"We are starting to rebuild again, and we have no choice."
EGPAF's Rhoda Igweta joined @avac.org and Gilead Sciences for a conversation with @devex.com on the sidelines of #WHA79 about the promise and pitfalls of lenacapavir.
www.devex.com/news/the-pro...
Lenacapavir, the new HIV prevention drug from Gilead Sciences, is both a potential game changer and a high-stakes test of the costs of global health funding cuts.
